Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

p> Marketing, general

and administrative 11,198 11,170 2,400 2,945

Total operating

expenses 46,062 42,220 10,164 10,625

Interest income 1,786 2,648 363 644

Interest expense (1,053) (834) (281) (191)

Other expense (66) (105) (66) (76)

Change in valuation of

warrants 2,314 - 2,314 -

Total other income

(expense), net 2,981 1,709 2,330 377

Net loss $(43,081) $(40,511) $(7,834) $(10,248)

Historical net

loss per share:

Basic and diluted $(1.28) $(1.49) $(0.21) $(0.35)

Weighted-average

shares -

basic and

diluted 33,581,590 27,247,385 38,112,063 28,931,495

FAVRILLE, INC.

(a development stage company)

STATEMENTS OF CASH FLOWS

(in thousands)

Years ended December 31,

2007 2006

(unaudited)

Operating activities:

Net loss $(43,081) $(40,511)

Adjustments to reconcile net loss to net cash

used in operating activities:

Depreciation and amortization 3,449 2,133

Stock-based compensation 4,584 4,010

Amortization of premium/discount on short-term

investments (412) (638)

Change in valuation of warrants (2,314) -

Other
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... LAKES, N.J. , July 22, 2014 The ... BDX ) has declared a quarterly dividend of ... to holders of record on September 9, 2014. The indicated ... About BD BD is a leading medical technology ... of the world,s most pressing and evolving health needs. Our ...
(Date:7/22/2014)... 22, 2014 Even within a phylum so full of ... among other arthropods for its cruelty -- at least to ... the fly is a most predatory sort of parasite. It ... a smear of larvae, and leaves its wicked brood to ... , None of this would be possible without the fly,s ...
(Date:7/22/2014)... from the National Institute of Standards and Technology ... demonstrated a new design for an atomic clock ... or a microcomb. , The microcomb clock, featured ... the new journal Optica ,* is the ... and its accurate conversion of optical frequencies to ...
(Date:7/22/2014)... of rod-shaped metal nanoparticles in water with ultrasound and ... bits. Why? No one yet knows exactly. But researchers ... have clocked their speedand it,s fast. At up to ... faster than any nanoscale object submerged in liquid ever ... opened up the possibility that they could be used ...
Breaking Biology Technology:Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4'Comb on a chip' powers new NIST/Caltech atomic clock design 2NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2
... , , ROCKVILLE, Md., July 21 ... appointment of John J. Trizzino as Senior Vice President, International ... Trizzino will report directly to Dr. Rahul Singhvi, Novavax,s President ... managing the company,s international alliances with pharmaceutical companies and all ...
... ... is pleased the U.S. Environmental Protection Agency will allow farmers the ability to improve upon ... for SmartStax, an insect-protection and weed control platform in corn, to 5 percent in the ... ...
... , , NEWARK, N.J., July 21 ... a specialty chemical technology based Life Science Company announced ... protocol testing, BioNeutral,s Ygiene(TM) Hospital Grade Antimicrobial passed the ... all 5.4 million spores of Clostridium difficile ...
Cached Biology Technology:Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances 2EPA Refuge Determination Positive for the Environment 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3
(Date:7/22/2014)... of both still images and video of artistic ... Forty-four still images were chosen from more than ... and alumni representing more than 25 different University ... 50 submissions. , Zach Donnell, a graduate student ... organizers, noted that the exhibit highlights the interplay ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2014. Revenue ... increase of 53% compared to $4.4 million in the same ... the second quarter of 2014 was $1.4 million compared to ... in revenue and operating income was driven by higher sales ...
(Date:7/22/2014)... science and engineering professor with an expertise in big ... Foundation grant worth more than $600,000 to develop an ... Heng Huang, an associate professor, will lead the project ... Computer Science and Engineering department. Scientists are compiling and ... number of genes involved in fruit fly development are ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7UT Arlington big data team wins $600,000 NSF grant to build gene expression database 2
... Researchers speaking in the first plenary session of the ... (IAS 2011) have today offered insights into current and ... developments over the past two years are beginning ... policy. The presentations reflect the breadth of expertise ...
... trailing a long length of rope behind you is not ... to manoeuvre, and can get tangled up or stuck on ... apart during cell division. The chromosomes are pulled by their ... Just like climbers carry their rope coiled up, cells make ...
... PHILADELPHIA The use of trastuzumab, chemotherapy and ... improved survival from the time central nervous system metastases ... researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now ... chemotherapy, even if cancer spreads to the brain." ...
Cached Biology News:Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 2Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 3Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 4Keeping it together 2Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients 2
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: